ML00253764

Cat. No.:	HY-124740
CAS No.:	681847-92-7
Molecular Formula:	$C_{18}H_{18}BrFN_2O$
Molecular Weight:	377.25
Target:	Melanocortin Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 66.67 mg/mL (176.73 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	2.6508 mL	13.2538 mL	26.5076 mL
	5 mM	0.5302 mL	2.6508 mL	5.3015 mL
	10 mM	0.2651 mL	1.3254 mL	2.6508 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

ML00253764 is a selective melanocortin receptor 4 (MC4R) antagonist, can induce apoptosis by inhibiting ERK1/2 and Akt phosphorylation, and has anticancer activity[1].

In Vitro

ML00253764 (0.001-50 μM, 24 h or 72 h) has significant time- and concentration-dependent inhibitory activity on the proliferation of human glioblastoma cells, and the IC_{50} value for U-118 cells is 6.56 μM, which can induce U -87 cells apoptosis and show significant inhibition of ERK1/2 phosphorylation in both cell lines[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

ML00253764(30 mg/kg, s.c., daily, 34 days) can inhibit inhibit tumor growth in CD nu/nu male mice infected with U-87 cells[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Francesca Vaglini, et al. Melanocortin Receptor-4 and Glioblastoma Cells: Effects of the Selective Antagonist ML00253764 Alone and in Combination with Temozolomide In Vitro and In Vivo. Mol Neurobiol. 2018 Jun;55(6):4984-4997.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA